AZOPT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AZOPT (AZOPT).
Carbonic anhydrase inhibitor; inhibits carbonic anhydrase II (CA-II) in ciliary processes, reducing aqueous humor secretion and intraocular pressure.
| Metabolism | Not significantly metabolized; primarily excreted unchanged in urine via renal tubular secretion. |
| Excretion | Primarily renal excretion as unchanged drug (approximately 70% of a topically applied dose is absorbed systemically and excreted unchanged in urine); minimal biliary/fecal elimination (<5%). |
| Half-life | Terminal elimination half-life is approximately 111 minutes (1.85 hours) in plasma after topical ocular administration; prolonged in renal impairment (creatinine clearance <30 mL/min). |
| Protein binding | Approximately 33% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | Volume of distribution is approximately 0.35 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Ocular bioavailability is not quantified due to local administration; systemic bioavailability after topical ocular dosing is approximately 70% via nasolacrimal absorption. |
| Onset of Action | Onset of intraocular pressure reduction occurs within 2 hours after topical ocular administration. |
| Duration of Action | Duration of action is approximately 8-12 hours after a single topical dose, supporting twice-daily dosing. |
One drop in the affected eye(s) twice daily. Instill at least 10 minutes apart from other ophthalmic medications.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No dosage adjustment required for systemic absorption is minimal. However, use caution in severe renal impairment (CrCl <30 mL/min) due to potential metabolite accumulation. |
| Liver impairment | No dosage adjustment required for systemic absorption is minimal. Use caution in severe hepatic impairment (Child-Pugh class C) due to limited data. |
| Pediatric use | Approved for children ≥2 years: one drop in the affected eye(s) twice daily. For children <2 years: safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required. Monitor for ocular irritation and systemic effects, as elderly patients may be more sensitive to adverse reactions such as hypotension or fatigue. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AZOPT (AZOPT).
| Breastfeeding | It is not known if brinzolamide is excreted in human milk. In animal studies, brinzolamide was detected in milk of lactating rats. Caution is advised; consider risk vs benefit. M/P ratio: unknown. |
| Teratogenic Risk | Pregnancy Category C. No adequate studies in pregnant women. In animal studies, brinzolamide (active ingredient) showed no teratogenic effects at oral doses up to 6 mg/kg/day in rabbits and 20 mg/kg/day in rats. However, due to potential for fetal harm (systemic carbonic anhydrase inhibition causing acidosis), use only if clearly needed. First trimester: avoid if possible; second/third trimesters: monitor for maternal acidosis. |
■ FDA Black Box Warning
None
| Common Effects | Blurred vision Bitter taste |
| Serious Effects |
["Hypersensitivity to brinzolamide or any sulfonamides","Severe renal impairment (CrCl <30 mL/min) or hyperchloremic acidosis"]
| Precautions | ["Sulfonamide allergy (cross-reactivity possible)","Corneal endothelial damage (risk increased with low endothelial cell count)","Bacterial keratitis (with concomitant use of topical corticosteroids or ocular trauma)","Contaminated dropper tip may cause ocular infections"] |
| Food/Dietary | No significant food interactions known. However, avoid excessive salt intake if using systemic carbonic anhydrase inhibitors; for AZOPT, ocular use minimizes systemic effects, but caution in patients with electrolyte imbalances. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, acid-base balance, and renal function periodically. Fetal monitoring: ultrasound for growth and amniotic fluid volume if used long-term. |
| Fertility Effects | No human data on fertility effects. In animal studies, no impairment of fertility was observed in rats at oral doses up to 18 mg/kg/day. |
| Clinical Pearls | AZOPT (brinzolamide ophthalmic suspension) is a carbonic anhydrase inhibitor used for lowering intraocular pressure in ocular hypertension or open-angle glaucoma. Shake well before use; may cause transient blurred vision. Use with caution in sulfonamide allergy patients. Monitor for corneal edema and electrolyte disturbances in prolonged use. |
| Patient Advice | Shake the bottle vigorously before each use. · Remove contact lenses before instilling and wait at least 15 minutes before reinserting. · Apply pressure to the tear duct (punctal occlusion) for 1 minute after instillation to reduce systemic absorption. · Do not touch the dropper tip to any surface to avoid contamination. · May cause temporary blurred vision; avoid driving or operating machinery until vision clears. · Report any eye pain, redness, or vision changes to your healthcare provider. |